Information  X 
Enter a valid email address

Abingdon Health PLC (ABDX)

  Print   

Tuesday 29 December, 2020

Abingdon Health PLC

AbC-19TM Rapid Test Update

RNS Number : 9380J
Abingdon Health PLC
29 December 2020
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN OR SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT

 

 

AbC-19TM Rapid Test Update

 

York, U.K. 29 December 2020:  Abingdon Health plc (AIM: ABDX) ("Abingdon" or "the Company"), a lateral flow diagnostics company providing contract service solutions to a global client base in the healthcare sector and other industries, today provides an update on the AbC-19TM Rapid Test.

 

Abingdon continues to liaise with the UK Medicines and Healthcare products Regulatory Agency (MHRA) regarding approval for home use and self-test of the AbC-19TM Rapid Test for antibodies to the spike protein of the SARS-CoV-2 virus. The Company announced the CE marking of the product for professional use on 30 July 2020. Whilst, as previously disclosed, the Department of Health and Social Care (DHSC) has the option to cancel its Supply of Goods Contract with the Company if a CE mark had not been granted for home use by 25 December 2020, Abingdon continues to work constructively MHRA to try to enable such authorisation.   The Supply of Goods Contract ends on 14th February 2021.  

 

Whereas the DHSC has right of first refusal for supplies of the AbC-19TM Rapid Test, the Company's regulatory department is liaising with regulatory authorities in other jurisdictions around the world to allow use of the product. For example, to allow the continued validity of the current CE marking post Brexit, Abingdon Health, as legal manufacturer via its agent, has successfully registered the AbC-19 Rapid Test with the Maltese Medicines Authority. This means that the CE mark, for professional use, will continue to apply across the European Union after 1 January 2021. The UK-RTC, of which the Company is a member, continues to liaise with customers and regulatory authorities in other international territories. Abingdon's regulatory department is currently working with UK-RTC partners on regulatory approval in a total of 27 territories.

 

Enquiries:

Abingdon Heath plc



Chris Yates

Chief Executive Officer

Via Consilium

Chris Hand

Non-Executive Chairman


Scott Page

Finance Director





N+1 Singer

Sole Broker and NOMAD

Tel: +44 (0) 20 7496 3000

Shaun Dobson, Pete Steel and Alex Bond (Corporate Finance)



Tom Salvesen (Corporate Broking)






Consilium

Financial PR

Tel: +44 (0) 7720 088 468

Matthew Neal


[email protected]

Mary-Jane Elliott 



Lindsey Neville



 

 

 

About Abingdon Health

 

Established in 2008, Abingdon Health is a lateral flow diagnostics company providing contract service solutions to a global client base in the healthcare sector and other industries. Services offered by the Company to its clients including product development, regulatory support, technology transfer and commercial manufacturing.

 

The Company has developed and is manufacturing the AbC-19TM Rapid Test, an antibody test for Covid-19 indicating whether a person is generating IgG antibodies to the spike protein of the SARS-CoV-2 virus. The Company is also working on the transfer of customers' Covid-19 antigen tests to manufacture, and is also manufacturing a component of a rapid PCR (polymerase chain reaction) test.  The Company also produces lateral flow tests covering non-Covid-19 applications in areas such as infectious disease, oncology, animal health and environmental testing.

 

The Company's main country of operation is the United Kingdom.

 

For more information visit www.abingdonhealth.com

 

About UK RTC

 

The UK-RTC was established by Abingdon Health, Omega Diagnostics, BBI Solutions, CIGA Healthcare and Oxford University.

 

About AbC19™ Rapid Test 

 

The AbC-19TM IgG lateral flow assay is targeted at IgG antibodies to the full spike protein of SARS-CoV-2 (COVID19) to indicate a measure of immune response (aligned with neutralizing antibodies).

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFVLLLBLLZFBZ

a d v e r t i s e m e n t